GlassScriptPhysician profile
Dayron Ortega
NPI 1437684693
$1,420.06
in general payments reported to CMS, 2019-2025
21 companies · $32.27 in 2025
The $32.27 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $87.46 · 2022: $910 · 2023: $390 · 2025: $32.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $390 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $389.89 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $246.54 | 2022-2023 | Jardiance, Trulicity, Mounjaro |
| Dexcom, INC. | $215.50 | 2022-2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Corcept Therapeutics | $192.28 | 2022 | |
| Xeris Pharmaceuticals, INC. | $163.86 | 2021-2023 | Recorlev, Gvoke Hypopen |
| Amgen INC. | $100.43 | 2021-2022 | |
| Insulet Corporation | $63.48 | 2022-2023 | Omnipod |
| Sanofi-Aventis U.S. LLC | $54.57 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.48 | 2022 | |
| Novo Nordisk INC | $44.56 | 2022-2025 | |
| Recordati_rare_diseases_inc. | $42.94 | 2022 | |
| Merck Sharp & Dohme LLC | $40.76 | 2022 | |
| Horizon Therapeutics Plc | $35.54 | 2022-2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $23.99 | 2023 | |
| Medtronic, INC. | $23.08 | 2022 | |
| Mannkind Corporation | $19.68 | 2023 | Afrezza |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amryt Pharma Holdings LTD | $19.61 | 2023 | Myalept |
| Ibsa Pharma INC. | $19.16 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $19.03 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.00 | 2022 | |
| Tandem Diabetes Care, INC. | $13.57 | 2022 | |
| Nevro Corp. | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dayron Ortega listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.